Accounts Receivables - Epizyme Inc (F:EPE) - Alpha Spread
E

Epizyme Inc
F:EPE

Watchlist Manager
Epizyme Inc
F:EPE
Watchlist
Price: 559 EUR 3.33%
Market Cap: 92.2B EUR
Have any thoughts about
Epizyme Inc?
Write Note

Epizyme Inc
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Epizyme Inc
Accounts Receivables Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
E
Epizyme Inc
F:EPE
Accounts Receivables
$11.2m
CAGR 3-Years
-6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Accounts Receivables
$11.7B
CAGR 3-Years
6%
CAGR 5-Years
16%
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Accounts Receivables
$4.7B
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Accounts Receivables
$6.9B
CAGR 3-Years
16%
CAGR 5-Years
13%
CAGR 10-Years
10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accounts Receivables
$1.7B
CAGR 3-Years
21%
CAGR 5-Years
29%
CAGR 10-Years
35%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accounts Receivables
$5.7B
CAGR 3-Years
-7%
CAGR 5-Years
18%
CAGR 10-Years
20%

See Also

What is Epizyme Inc's Accounts Receivables?
Accounts Receivables
11.2m USD

Based on the financial report for Jun 30, 2022, Epizyme Inc's Accounts Receivables amounts to 11.2m USD.

What is Epizyme Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 3Y
-6%

Over the last year, the Accounts Receivables growth was 57%. The average annual Accounts Receivables growth rates for Epizyme Inc have been -6% over the past three years .

Back to Top